Mindray is one of the leading global providers of medical devices and solutions. Firmly committed to our mission of “sharing medical technologies with the world”, we are dedicated to innovation in the fields of Patient Monitoring & Life Support, In-Vitro Diagnostics, and Medical Imaging.
Headquartered in Shenzhen, China, and listed on the New York Stock Exchange, Mindray possesses a sound distribution and service network with subsidiaries in 22 countries in North and Latin America, Europe, Africa and Asia-Pacific. While improving the quality of care, we help reducing its cost, making it more accessible to a larger part of humanity.
Since its foundation in 1991, Mindray’s development has been driven by innovation. Mindray has built up a global R&D network with research centers in Seattle, New Jersey, Miami, Stockholm, Shenzhen, Beijing, Nanjing, Chengdu, Xi’an and Shanghai.
Today, Mindray’s products and services can be found in healthcare facilities in over 190 countries and regions. Inspired by the needs of our customers, we adopt advanced technologies and transform them into accessible innovation, bringing healthcare within reach.
1991, Founded in Shenzhen, China
1993, Developed China's first multi-parameter patient monitor
1995, ISO 9001 certified by TUV
1998, Developed China's first 3-part differential haematology analyser
2000, Received first CE Mark clearance; began exporting products overseas
2001, Developed China's first digital diagnostic ultrasound imaging system
2003, Developed China's first automatic chemistry analyser
2004, Received first FDA 510(k) clearance; first products exported to the US Market
2006, Developed China's first 5-part differential haematology analyser
2006, Developed China's first digital colour Doppler ultrasound imaging system
2006, Listed on New York Stock Exchange under the ticker symbol "MR"
2007, Received the "2006 Global Market Penetration Leadership" and the "2007 Patient Monitoring
Global Excellence" awards from the global growth consulting company, Frost & Sullivan
2008, Acquired Datascope's patient monitoring business, becoming the third-largest player in the global patient monitoring device industry
2010, Received the "2010 European Patient Monitoring Excellence in Globalisation Award" from the global growth consulting company, Frost & Sullivan
2010, Received the " 2010 Frost & Sullivan Award for Excellence in Innovation "
2011, Acquired a controlling stake in Shenke, Hyssen, Greenlander IT and TDR Biotech
2011, Received the “ 2011 Frost & Sullivan Excellence in Growth Award”
Leave a Reply